grant

Epigenetic mechanisms of HAND pathogenesis

Organization GEORGE WASHINGTON UNIVERSITYLocation WASHINGTON, UNITED STATESPosted 13 Sept 2024Deadline 31 Aug 2026
NIHUS FederalResearch GrantFY2026AIDS VirusATAC sequencingATAC-seqATACseqAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusAddressAffectAssay for Transposase-Accessible Chromatin using sequencingAstrocytesAstrocytusAstrogliaBBB penetrationBioinformaticsBlood monocyteBrainBrain Nervous SystemCell BodyCell NucleusCellsCholesterol HomeostasisChromatinChronicCollaborationsData SetDevelopmentDrug usageElementsEncephalonEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessExploratory/Developmental GrantExposure toFoundationsFutureGene TranscriptionGenesGenetic TranscriptionGliaGlial CellsGoalsHIVHIV 1 associated neurocognitive disorderHIV InfectionsHIV associated neurocognitive deficitHIV associated neurocognitive impairmentHIV individualsHIV induced neurocognitive deficitHIV induced neurocognitive impairmentHIV infected individualsHIV infected personsHIV interventionHIV loadHIV neurocognitive impairmentHIV peopleHIV plasma viral loadHIV positive individualsHIV positive peopleHIV replicationHIV therapeuticHIV therapyHIV treatmentHIV viral burdenHIV viral infectionHIV viral loadHIV viral replicationHIV virus infectionHIV-1HIV-1 associated neurocognitive deficitHIV-1 associated neurocognitive disorderHIV-1 associated neurocognitive impairmentHIV-1 infectionHIV-1 interventionHIV-1 loadHIV-1 replicationHIV-1 therapeuticHIV-1 therapyHIV-1 treatmentHIV-1 viral burdenHIV-1 viral loadHIV-1 viral replicationHIV-1 virus replicationHIV-IHIV-associated neurocognitive disorderHIV1Hortega cellHuman Immunodeficiency Virus Type 1Human Immunodeficiency Virus therapyHuman Immunodeficiency Virus treatmentHuman Immunodeficiency Virus-1Human Immunodeficiency VirusesHuman immunodeficiency virus 1ImmunityImmunologyIn VitroIndividualInfection by HIV-1Infection from HIV-1Infection of HIV-1InflammationInflammatoryInflammatory ResponseInnate Immune ResponseInvestigationInvestigatorsKolliker's reticulumLAV-HTLV-IIILymphadenopathy-Associated VirusMarrow monocyteMemoryMetabolicMethodologyMicrogliaModelingModificationMolecularMyeloid CellsNeurobiologyNeurocognitive Impairment in HIVNeurocognitive Impairment in HIV-1NeurogliaNeuroglial CellsNon-Polyadenylated RNANon-neuronal cellNonneuronal cellNucleusOligodendrocytesOligodendrocytusOligodendrogliaOligodendroglia CellOutcomePLWHPWHPathogenesisPathogenicityPathogenicity FactorsPathway interactionsPeripheralPhenotypeQOLQuality of lifeR21 MechanismR21 ProgramRNARNA ExpressionRNA Gene ProductsResearch PersonnelResearchersRibonucleic AcidStimulusTestingTherapeuticTrainingTranscriptionViral Gene ProductsViral Gene ProteinsViral ProteinsVirulence FactorsVirusVirus-HIVantiretroviral therapyantiretroviral treatmentassay for transposase accessible chromatin followed by sequencingassay for transposase accessible chromatin seqassay for transposase accessible chromatin sequencingassay for transposase-accessible chromatin with sequencingastrocytic gliablood-brain barrier penetrationbloodbrain barrier penetrationbrain cellcell typecholesterol metabolismco-morbidco-morbiditycomorbiditydevelop therapydevelopmentaldrug useepigenetic memoryepigeneticallyexploratory developmental studyextracellular vesiclesgitter cellhigh rewardhigh riskhuman immunodeficiency virus infectionhuman immunodeficiency virus replicationhuman immunodeficiency virus-1 replicationhumanized micehumanized mouseindividuals infected with HIVindividuals with HIVindividuals with human immunodeficiency virusinfected with HIVinfected with human immunodeficiency virusinnovateinnovationinnovativeintervention developmentmesogliamicroglial cellmicrogliocytemonocytemouse modelmurine modelnefnef Gene Productsnef Proteinnerve cementneural inflammationneurobiologicalneuroinflammationneuroinflammatoryneuropathologicneuropathologicalneuropathologynovelpathogenpathwaypeople infected with HIVpeople infected with human immunodeficiency viruspeople living with HIVpeople with HIVpeople with human immunodeficiency virusperivascular glial cellresponsetherapy developmenttreat HIVtreat Human Immunodeficiency Virustreatment developmentvirologyvirus protein
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

HIV-associated neurocognitive disorders (HAND) remain among the most prominent HIV co-morbidities in the
era of ART-treated HIV infection. Persistent neuroinflammation is a recognized pathogenic feature of HAND, but

the reason(s) for the inflammation persisting after initiation of ART remain incompletely understood. Our recent

studies demonstrated that monocytes exposed to EVs carrying HIV-1 protein Nef (Nef EVs) acquire pro-

inflammatory epigenetic memory that promotes exacerbated responses to inflammatory stimuli when Nef is long

gone. The mechanism of this effect is similar to “trained immunity”, a concept that stipulates that an exposure to

a pathogen may not only trigger an innate immune response in myeloid cells, but also induce long-lasting

metabolic and epigenetic alterations causing innate inflammatory responses to be faster and more robust. We

hypothesize that this effect of Nef may also target brain myeloid cells, microglia, and possibly other brain cells,

astrocytes and oligodendrocytes. If contribution of this mechanism is confirmed, that would imply that even

complete elimination of the virus or virus-related pathogenic factors may not be sufficient to fully abolish

neuropathology in HIV-infected individuals, as brain cells will keep their pro-inflammatory status. The following

Specific Aims will be pursued to test this hypothesis. SA1. To characterize epigenetic modifications induced

by HIV and Nef EVs and assess their contribution to neuroinflammation. In this Aim, we will characterize

epigenetic and transcriptional effects of HIV infection and Nef EV treatment in humanized mice. Results of

snATAC-seq in this model will be compared to epigenetic dataset obtained from brains of PLWH. SA2. To

establish how Nef EVs induce epigenetic modifications in brain cells contributing to neuroinflammation.

Here, we will establish the cell type-specific mechanisms of inflammatory modifications induced by Nef EVs. This

study is a continuation of the long-term collaboration between Drs. Bukrinsky and Sviridov, who discovered the

training effect of Nef on myeloid cells. The proposed project is fully consistent with the R21 mechanism, as it

investigates a novel phenomenon and involves high risk high reward studies.

Grant Number: 3R21NS137986-01A1S1
NIH Institute/Center: NIH

Principal Investigator: MICHAEL BUKRINSKY

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →